SHD's very own Andrew Offer, CFA will be serving on the Medical Device Panel at RESI JPM 2025 where he will discuss the current state of the medical device investing landscape, how to navigate FDA regulatory hurdles, and the type of data that excites early-stage investors. Tune in! #RESIJPM #JPM2025
Scientific Health Development
投资管ç†
Dallas，Texas 484 ä½å…³æ³¨è€…
Investment company focused on early-stage, innovative medical devices.
关于我们
SHD invests in early-stage medical device companies at the intersection of enhanced patient outcomes, improved economics, and usability.
- 网站
-
https://www.shdpartners.com
Scientific Health Development的外部链接
- 所属行业
- 投资管ç†
- 规模
- 2-10 人
- 总部
- Dallas，Texas
- 类型
- åˆè¥ä¼ä¸š
地点
-
主è¦
获å–路线
8144 Walnut Hill Lane
Suite 905
US，Texas，Dallas，75231
Scientific Health Development员工
动æ€
-
We are proud to announce SHD portfolio company Mindera Health's strategic partnership with the National Psoriasis Foundation. We are excited to be able to offer a solution for patients struggling to find the right treatment for their psoriasis. #Psoriasis #Mind.PX
As a leader in #precisionmedicine for dermatological conditions, today we announce a strategic partnership with the National Psoriasis Foundation, the largest patient advocacy organization dedicated to serving those with #psoriasis and psoriatic arthritis. Read More:https://lnkd.in/gY6R3DuR
-
Jupiter Endovascular, a spinoff from SHD III portfolio company Neptune Medical, has enrolled the first US patient in the SPIRARE II pivotal trial using the Vertex system to treat PE. Congratulations to Carl St. Bernard, Alex Tilson, and the rest of the Jupiter team!
First in the USA! This week, Mitchell Weinberg and Vincent Gallo performed the first #Endoportal Control procedure in the US at Northwell Health Staten Island University Hospital, where they successfully treated the first pulmonary embolism patient in the SPIRARE II pivotal trial using the Vertex Pulmonary Embolectomy System. This significant milestone in our quest to revolutionize endovascular medicine builds upon the momentum from our recent FDA IDE approval and our first cases in the currently-enrolling SPIRARE I European study. We would like to extend a big thank-you to our SPIRARE investigational team for their support and dedication, and to Brandon Dilluvio, CCRC in particular for his support in facilitating this first US procedure. Read more: https://lnkd.in/gv4frN7b *The Vertex Pulmonary Embolectomy System is for investigational use only.
-
-
SHD III portfolio company Koya Medical, Inc. announced impressive clinical results from the TEAYS study last week in which the Dayspring patient arm showed improved efficacy, quality of life, and adherence compared to patients on traditional pneumatic compression devices. We are excited for Andy Doraiswamy, Damian Rippole, and the whole Koya team, and are proud to have been an early investor and continued supporter of what they are building. https://lnkd.in/gYdic3c4
-
-
SHD is pleased to announce that SHD Fund III portfolio company Neptune Medical has successfully closed on a $97M Series D financing led by Olympus Corporation of the Americas to further develop their robotic platform for gastrointestinal indications. Jupiter Endovascular was spun out as part of the financing and will focus on endovascular therapies. Congratulations to Alex Tilson, Niraj Shah, and the rest of the team on this tremendous milestone! https://lnkd.in/gYs4CAMk
-
Strong companies find a way regardless of the environment.?Congratulations to Mindera Health on its recent financing and thank you to Nasdaq for hosting the team at your HQ to help us celebrate!?SHD is proud to have been Mindera’s first institutional capital years ago and is excited for what is yet to come. #precisionmedicine #medicaldevice #venturecapital #MindPx #MinderaHealth #psoriasis
-
-
We are excited to share that SHD IV portfolio company Liberate Medical has begun enrollment of the PREVENT pivotal trial. The 25 clinical site, 272 patient trial, partially funded by the US Department of Defense, aims to reduce the duration of mechanical ventilation in patients at risk of being difficult to wean. Congrats to Angus McLachlan and the entire Liberate Medical team!
?? Exciting News from Liberate Medical! ?? We're thrilled to announce the launch of the PREVENT trial - a pivotal clinical trial that aims to demonstrate that our VentFree? Respiratory Muscle Stimulator reduces duration of invasive mechanical ventilation in patients at risk of being difficult to wean. ?? Thank you and congratulations to everyone who has contributed to the successful launch of this important study. A special mention goes to The Prince of Wales Hospital, Baylor College of Medicine, and Providence Regional Medical Center Everett - Colby Campus who were the first sites to enroll patients worldwide! ?? The PREVENT study aims to enroll 272 patients from up to 25 sites across the US, Australia and the EU and was made possible with a significant $6.5M grant from the US Department of Defense. ?? Read the full press release here: https://lnkd.in/gMRYuwbK